Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy

Hill, 2008, Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity., J Pharmacol Exp Ther, 327, 610, 10.1124/jpet.108.139006

Herlaar, 1999, p38 MARK signaling cascades in inflammatory disease., Mol Med Today, 5, 439, 10.1016/S1357-4310(99)01544-0

Guan, 1998, Induction of cyclooxygenase-2 by the activated MEKK1 → SEK1/MKK4 → p38 mitogen-activated protein kinase pathway., J Biol Chem, 273, 12901, 10.1074/jbc.273.21.12901

Lee, 1999, p38 mitogen-activated protein kinase inhibitors—mechanisms and therapeutic potentials., Pharmacol Ther, 82, 389, 10.1016/S0163-7258(99)00008-X

Hale, 1999, Differential expression and activation of p38 mitogen-activated protein kinase α, β, γ, and δ in inflammatory cell lineages., J Immunol, 162, 4246, 10.4049/jimmunol.162.7.4246

Schett, 2000, Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis., Arthritis Rheum, 43, 2501, 10.1002/1529-0131(200011)43:11<2501::AID-ANR18>3.0.CO;2-K

Korb, 2006, Differential tissue expression and activation of p38 MAPK α, β, γ, and δ isoforms in rheumatoid arthritis., Arthritis Rheum, 54, 2745, 10.1002/art.22080

Arnett, 1988, The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis., Arthritis Rheum, 31, 315, 10.1002/art.1780310302

Felson, 1993, T he American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials., Arth Rheum, 36, 729, 10.1002/art.1780360601

International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline. Clinical safety data management: definitions and standards for expedited reporting, E2A; 27 October 1994. http://www.ich.org/LOB/media/MEDIA436.pdf (accessed 2 Dec 2009).

Cohen, 2009, Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study in patients with active rheumatoid arthritis., Arthritis Rheum, 60, 335, 10.1002/art.24266

Damjanov N, Kauffman R, Spencer-Green GT,. Safety and efficacy of VX-702, a p38 MAP kinase inhibitor, in rheumatoid arthritis. Ann Rheum Dis 2008;67(Suppl II):125.

Schreiber, 2006, Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial., Clin Gastroenterol Hepatol, 4, 325, 10.1016/j.cgh.2005.11.013

Laffitte, 2005, Kinase inhibitor-induced pustules., Dermatology, 211, 305, 10.1159/000088496

Genovese, 2009, Inhibition of p38: has the fat lady sung?, Arthritis Rheum, 60, 317, 10.1002/art.24264